Sera PrognosticsSERA -1.63%70 FCF Yield % is -38.91 as of Jun. 25, 2026. GuruFocus rates SERA with a GF Score™ of 70/100 and a GF Value™ of $1.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Sera Prognostics ranks worse than 89.71% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Sera Prognostics FCF Yield % Related Terms
Sera Prognostics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Sera Prognostics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sera Prognostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a FCF Yield % of -38.91 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sera Prognostics and its competitors. According to the industry distribution chart, Sera Prognostics ranks #767 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 89.7%.
Is Sera Prognostics' FCF Yield % too high?
Sera Prognostics' current FCF Yield % is -38.91. Based on the distribution chart, Sera Prognostics ranks #767 out of 855 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sera Prognostics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' FCF Yield % compare to ECOR and OM?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #767 out of 855 companies for FCF Yield %. This places Sera Prognostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sera Prognostics and its competitors. Sera Prognostics's current FCF Yield % is -38.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Fairly Valued. The stock's GF Value™ is $1.86, compared to a current price of $1.81 — trading 2.7% below its estimated fair value. The current FCF Yield % is -38.91. Sera Prognostics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Sera Prognostics (SERA), the current FCF Yield % is -38.91 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be undervalued.
The current stock price of $1.81 is trading 2.7% below its estimated GF Value™ of $1.86.
GuruFocus considers Sera Prognostics to be Fairly Valued.
Key valuation signals for SERA:
FCF Yield %: -38.91
GF Value™: $1.86 vs. price of $1.81 (2.7% below fair value)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
70GF Score
Get the complete analysis for SERA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
